Ardelyx, Inc. (ARDX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

0.5940

+0.0041

(+0.70%)

At close: 04:00PM EDT

0.6050

+0.01

(+1.85%)

After hours:

07:54PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Williams %R

View all chart patterns

Performance Outlook

Previous Close	0.5899
Open	0.5800
Bid	0.5830 x 1000
Ask	0.5935 x 1000
Day's Range	0.5750 - 0.6084
52 Week Range	0.4900 - 8.2470
Volume	1,762,552
Avg. Volume	3,587,191

Market Cap	85.892M
Beta (5Y Monthly)	1.85
PE Ratio (TTM)	N/A
EPS (TTM)	-1.3610
Earnings Date	Aug 11, 2022 - Aug 15, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	6.14

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ARDX

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Ardelyx, Inc.
Daily – Vickers Top Buyers & Sellers for 04/25/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Rating
Fair Value
Economic Moat
2 months agoArgus Research

All

PR Newswire
Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on June 28, 2022, the compensation committee of the company's board of directors granted six new non-executive employees options to purchase an aggregate of 332,483 shares of the company's common stock, and granted an aggregate of 83,375 Restricted Stock Units (RSUs) to eight new
- Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  GlobeNewswire
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
  GlobeNewswire
PR Newswire
Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the company may receive up to $20 million from HealthCare Royalty Partners (HealthCare Royalty) from the sale of its future royalties and sales milestones from Kyowa Kirin Co., Ltd (Kyowa Kirin), its collaboration partner in Japan for the commercialization of tenapanor for hyperp
PR Newswire
Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has informed the company that a meeting of the Cardiovascular and Renal Drugs Advisory Committee (Advisory Committee) is tentatively scheduled for November 16, 2022. The Advisory Committee will discuss the company's New Drug Application